Harvard Bioscience
HBIO
94 hedge funds and large institutions have $145M invested in Harvard Bioscience in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 6 closing their positions.
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
18% more funds holding
Funds holding: 80 → 94 (+14)
2% more capital invested
Capital invested by funds: $143M → $145M (+$2.22M)
0.13% more ownership
Funds ownership: 7.43% → 7.56% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$1.98M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.79M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.43M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.09M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$986K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$4.23M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.61M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.42M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$846K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$650K |
HBIO Hedge Fund Activity: Q3 2018 in Review
94 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2018, worth a combined $145M — up 1.6% from $143M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new HBIO positions and 6 closed out — a net gain of 15 holders — while 35 added to existing stakes and 22 trimmed.
The largest buyer was Cadence Capital Management, opening a new position worth an estimated $1.98M. The largest seller was Segall Bryant & Hamill, cutting an estimated $4.23M.
- 94 institutional investors held Harvard Bioscience (HBIO) as of Q3 2018, up from 80 in Q2 2018.
- Funds reported $145M of Harvard Bioscience stock for Q3 2018, up 1.6% quarter-over-quarter.
- 21 funds opened new Harvard Bioscience positions in Q3 2018 and 6 closed out, a net change of +15 holders.
- The largest Harvard Bioscience buyer in Q3 2018 was Cadence Capital Management, an estimated $1.98M added.
- The largest Harvard Bioscience seller in Q3 2018 was Segall Bryant & Hamill, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2018.